Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Silence Therapeutics promotes Sedgwick to CEO role; Christély resigns

Silence Therapeutics promotes Sedgwick to CEO role; Christély resigns

Gene silencing specialist Silence Therapeutics (LON:SLN) announced today that Tony Sedgwick has been appointed the new CEO of the company following the resignation of Thomas Christély.

Sedgwick was formerly the chief business officer and his promotion takes effect immediately, the firm said.

Christély has resigned as a director for personal reasons but will ensure a smooth transition, the company added.

The company's chairman Jerry Randall said: "Tony has a great deal of relevant experience gained from the global pharmaceutical industry. He has made a very positive impact on Silence since joining in September last year and has demonstrated the right leadership skills needed as the company continues to gain momentum."

He thanked Christély for his many years of valuable service, on behalf of the board, and wished him well for the future.

New chief executive Sedgwick said that since joining the company, he had been excited about the opportunities ahead.

"We have already strengthened the business development team with the appointment of Dr Georg Buchner who will now take full responsibility for business development.

"The company's pipeline including Atu027 is making good progress and is endorsed by external partners," he said.

He added that in the next few years, he planned to increase the commercial focus of the company.

The company develops siRNAs, which are double-stranded molecules that silence certain genes. These are being developed to be used in targeting multiple disease types, including cancer.

Last month, the company announced a collaboration agreement with
US–based firm miRagen to assess delivery methods for new, micro versions of gene silencing technology to treat serious diseases.

Giles_55af4ddca6481.jpg
Why Invest In Silence Therapeutics plc? Read More Here

Register here to be notified of future SLN Company articles
View full SLN profile

Silence Therapeutics plc Timeline

Newswire
September 27 2016

Related Articles

A graphic of a tumour growing in the body
July 07 2016
Nanobiotix is a late clinical-stage nanomedicine company researching novel approaches to enhance radiotherapy for the local treatment of cancer.
GW_Pharma.png
January 11 2017
“[We are] entering a very exciting phase, which should result in the crystallisation of substantial value,” said chief executive, Dr Satu Vainikka.
newspaper with word cancer magnified
January 30 2017
The start of 2017 has seen some good trial results for its skin cancer treatment, as well as a collaboration deal that will accelerate the development of its lung cancer drug

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use